Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(17 sites)

United States

University of California Irvine, Orange, California

Golisano Children's Hospital, Fort Myers, Florida

The Foundation for Sickle Cell Disease, Hollywood, Florida

University of Maryland, Baltimore, Maryland

Detroit Medical Center, Detroit, Michigan

Henry Ford Health System, Detroit, Michigan

Mount Sinai Medical Center, New York, New York

Jacobi Medical Center, The Bronx, New York

Albert Einstein College of Medicine, The Bronx, New York

University of Cincinnati, Cincinnati, Ohio

The Ohio State University, Columbus, Ohio

University of Pittsburgh, Pittsburgh, Pennsylvania

Hillman Cancer Center, Pittsburgh, Pennsylvania

Virginia Commonwealth University, Richmond, Virginia

Turkey (Türkiye)

Hacettepe Universitesi, Ankara

Istanbul Universitesi, Istanbul

Özel Acibadem Adana Hastanesi, Seyhan